Strategies for developing clinical pharmacy services in ambulatory care: A hematology perspective

Abstract

Introduction: Patients with hematological malignancies and benign disorders are frequently exposed to high-risk pharmacotherapy requiring close monitoring for toxicity, drug-drug interactions, and medication adherence. Clinical pharmacists are integral members of multidisciplinary teams; however, the organization and impact of ambulatory clinical pharmacy services remain heterogeneous. Aim: The aim of the study is to systematically evaluate the implementation models and clinical impact of ambulatory clinical pharmacy services in hematology. Materials and Methods: A systematic literature review and comparative analysis were conducted using Web of Science, Scopus, and Google Scholar, focusing on studies addressing ambulatory hematology pharmacy practice. Results: Evidence supports structured, multifaceted service models based on comprehensive medication management, medication utilization review, and patient-centered care. Pharmacist-led interventions—including medication reconciliation, regimen validation, toxicity monitoring, and management of drug-related problems—improve medication safety and optimize therapy, while adherence support and patient education address key challenges in ambulatory care. However, substantial heterogeneity in service design, scope, and outcome reporting limits comparability and generalizability. The long-term clinical impact, including survival outcomes, remains insufficiently defined. Inconsistent implementation of standardized documentation and classification frameworks further constrains evaluation. Although multidisciplinary integration is critical for successful implementation, barriers such as limited resources, institutional variability, and inadequate reimbursement persist. Conclusion: Clinical pharmacists constitute a critical component of ambulatory hematology care, enhancing medication safety and therapeutic outcomes. The establishment of standardized service frameworks, harmonized documentation practices, and robust outcome metrics is imperative to substantiate their clinical and economic value.